Why Ohr Pharmaceuticals (OHRP) Stock Is Soaring Today

NEW YORK (TheStreet) -- Ohr Pharmaceuticals  (OHRP) soared Thursday after Vista Partners increased its price target on the stock to $31 from $14.

The stock plunged Tuesday after it reported results of its phase II study on its Squalamine eye drop. For more on that, read TheStreet's Adam Feuerstein's article here.

Ohr closed up 35.43%, or $2.59, to $9.90 on Thursday. More than 5.7 million shares changed hands, compared to the average volume of 401,319.

Must Read: Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

OHRP Price Chart

OHRP Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%